Navigation Links
New nanopharmaceutical may help overcome resistance to certain anticancer drugs
Date:10/21/2013

BOSTON The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 23.

Antiangiogenic drugs are anticancer drugs designed to cut off the blood supply that brings tumors the nutrients they need to grow and survive, thereby starving and killing the tumor cells. Over time, however, tumors usually develop resistance to these drugs, often because of the upregulation of a protein called HIF-1 alpha. This protein promotes tumor invasion, metastasis, and cancer stem cell formation, all of which make tumors more aggressive and unmanageable. Antiangiogenesis drugs, as a result, have achieved limited success in the treatment of cancers.

"Reducing or eliminating resistance to antiangiogenic drugs could have meaningful implications for cancer patients. Up until now, HIF-1alpha has been considered impossible to target safely, but CRLX101 may change that," said Scott Eliasof, Ph.D., vice president of Cerulean Pharma Inc., in Cambridge, Mass. "CRLX101 has been shown to inhibit HIF-1alpha, and the clinical data we have obtained to date suggest that it has limited side effects, which may permit it to be effectively combined with other drugs. We believe that CRLX101 may have the potential to manage resistance to antiangiogenic and radiation therapies.

"Based on our preclinical data, we believe CRLX101 may have the potential to have a significant effect on pathological complete response in rectal cancer patients and on overall survival duration in patients with ovarian and kidney cancers," he added.

CRLX101's payload is the toxic anticancer drug, camptothecin, chemically conjugated into nanoparticles of 20-30 nanometers in diameter, using polymeric materials. When CRLX101 is taken up by the tumor
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
2. Female and younger athletes take longer to overcome concussions
3. Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels
4. Avatars may help children with social anxiety overcome fears
5. Scientists develop new strategy to overcome drug-resistant childhood cancer
6. Some Kids May Overcome or Outgrow Egg Allergy, Study Suggests
7. New drug overcomes resistance in patients with rare sarcoma
8. Stop Sugar Cravings
9. How “21 Day Sugar Detox” Helps People Overcome Sugar Addiction – Health Review Center
10. Stroke damage in mice overcome by training that rewires brain centers
11. Boyd Lemon Launches Book: "Retirement: A Memoir and Guide," How to Overcome the Problems and Frustrations and Live a Fulfilling Retirement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... PROVIDENCE, R.I. [Brown University] As Congress adjourns this ... bills senators will step over on their way out ... (SGR) Repeal and Medicare Provider Payment Modernization Act of ... JAMA Surgery , Dr. Eli Adashi recounts what he ... originally bipartisan bill. The perennial trouble with how Medicare ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Boston, MA (PRWEB) September 17, 2014 ... have partnered to create a monthly concert series, ... arts organization From the Top, America’s premier national ... classically-trained young musicians. Many of the young musicians ... the Top. , “Boston Children’s Museum is fortunate ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
(Date:9/17/2014)... 17, 2014 StartX , a ... companies raising rounds of funding at its Summer Demo ... investors and media, was the first such gathering held ... to the university. The presentations were delivered on an ... StartX-QB3 Labs, a 2,000 square foot life science facility ...
Breaking Medicine News(10 mins):Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6
... to present findings at AMCP Conference in AprilST. ... Prime Therapeutics (Prime) revealed a significant reduction in ... a retrospective drug utilization review (RetroDUR) program paired ... research was recently published in the American Journal ...
... healing time and pain reduction, , , TUESDAY, April 14 ... production of stem cells appears to "jump-start" the bone-healing ... as fast as young people,s, suggest preliminary results released ... University of Rochester Medical Center in New York gave ...
... Expects to qualify for 180 days of sole marketing ... MYL ) today confirmed that the company and its ... Roche Inc. in connection with the filing of an ... and Drug Administration (FDA) for Capecitabine Tablets, 150 mg ...
... Pearl of Wisdom to Help Prevent Cervical Cancer UPPER MARLBORO, Md., ... knows about and benefits from the tools - the Pap test, ... from this disease. That,s the message that the Pearl of Wisdom(TM) ... women to get - and share - in honor of Mother,s ...
... Versus 2008 First Quarter; , EPS was $1.26, Equal to ... Johnson (NYSE: JNJ ) today announced sales of ... of 7.2% as compared to the first quarter of 2008. ... was 6.0%. Domestic sales declined 5.0%, while international sales declined ...
... The American Federation for Medical Research (AFMR) today has ... sectors to take action against the crisis in U.S. ... major U.S. government agencies, corporations and leading academic institutions ... clinical research from advancing in America. This lack of ...
Cached Medicine News:Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 2Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 3Health News:Slow-Healing Bones May Get Boost From Drug 2Health News:Slow-Healing Bones May Get Boost From Drug 3Health News:Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment 2Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 2Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 3Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 4Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 2Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 3Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 4Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 5Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 6Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 7Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 8Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 9Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 10Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 11Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 12Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 13Health News:The American Federation for Medical Research Unites Top Leaders to Mitigate U.S. Crisis in Clinical Research 2
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... 2020 Summary GlobalData,s ... to 2020", provides key market data on the ... value, in millions of US dollars, volume (in ... market segments - Female Sterilization Devices (Transcervical Sterilization ...
(Date:9/17/2014)... 2014 BRIC Biopsy Devices Market Outlook to ... report, "BRIC Biopsy Devices Market Outlook to 2020", provides ... The report provides value, in millions of US dollars, ... within market segments - Biopsy Guns (Disposable and Reusable ... (Disposable and Reusable Fine Aspiration Needles) and Disposable Vacuum-Assisted ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new ... provides key market data on the BRIC Gynecological ... of US dollars, volume (in units) and average ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and ...
Breaking Medicine Technology:North America Gynecological Devices Market Outlook to 2020 2North America Gynecological Devices Market Outlook to 2020 3BRIC Biopsy Devices Market Outlook to 2020 2BRIC Biopsy Devices Market Outlook to 2020 3BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3
... 2012  Ambit Biosciences and Teva Pharmaceutical Industries Limited (NASDAQ: ... of an Investigational New Drug application (IND)  with the U.S. ... (V600E) kinase inhibitor.  The IND filing ... as evidenced by data revealed in recent publications in ...
... - Atu027, a First in Class RNAi Therapy, Demonstrates Potential ... Biomarker Identified Silence Therapeutics to Announce New Data ... 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: ... (RNAi) therapeutics company, today announces that top line data from ...
Cached Medicine Technology:Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 2Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 3Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 4Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 5New Data from Silence's Atu027 Anticancer Trial Published at ASCO 2New Data from Silence's Atu027 Anticancer Trial Published at ASCO 3New Data from Silence's Atu027 Anticancer Trial Published at ASCO 4New Data from Silence's Atu027 Anticancer Trial Published at ASCO 5
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Standard Trephine...
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs....
Long Handled Trephine...
Medicine Products: